Are the effects of blood pressure lowering treatment diminishing?: meta-regression analyses

Clinical Hypertension

Table 2 Meta-regression analyses (Dependent variable: natural log of relative risk for all-cause mortality)

	Model 1M (single)			Model 2M (multiple)
Variable	exp(b)	95% CI	p-value	exp(b)	95% CI	p-value
Trial start year (per 10 years)	1.05	1.02–1.09	0.004	1.05	0.99–1.10	0.078
	Adjusted R² = 34.8%
Age (per 10 years)	1.01	0.96–1.07	0.633	0.97	0.91–1.03	0.311
	Adjusted R² = −1.8%
Sample size (per 1000 participants)	1.01	1.00–1.01	0.012	1.00	1.00–1.01	0.188
	Adjusted R² = 32.7%
Baseline SBP (per 10 mmHg)	0.99	0.97–1.01	0.414	1.02	0.99–1.05	0.201
	Adjusted R² = −2.3%
SBP difference (per 10 mmHg)	0.93	0.87–0.99	0.033	1.00	0.90–1.11	0.990
	Adjusted R² = 28.3%
Region (per category)
Mixed region	1 (ref)			1 (ref)
North America	0.85	0.77–0.93	0.001	0.89	0.78–1.00	0.055
Europe	0.93	0.85–1.00	0.062	0.95	0.85–1.06	0.341
Asia	0.80	0.70–0.91	0.001	0.84	0.73–0.97	0.020
Oceania	0.69	0.46–1.04	0.077
South Africa	0.98	0.06–16.9	0.988	0.94	0.05–16.3	0.968
	Adjusted R² = 61.9%
Adjusted R²				68.9%
K				74

exp(b) the exponentiation of the b coefficient; ref. reference; CI confidence interval; K number of trials

ISSN: 2056-5909